Ardsley Advisory Partners LP Has $7.28 Million Stock Holdings in ADMA Biologics Inc $ADMA

Ardsley Advisory Partners LP lifted its position in ADMA Biologics Inc (NASDAQ:ADMA) by 33.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 400,000 shares of the biotechnology company’s stock after purchasing an additional 100,000 shares during the quarter. Ardsley Advisory Partners LP owned 0.17% of ADMA Biologics worth $7,284,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. SVB Wealth LLC bought a new stake in ADMA Biologics during the first quarter worth about $35,000. Cullen Frost Bankers Inc. raised its stake in shares of ADMA Biologics by 112.5% in the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 1,081 shares during the last quarter. Toth Financial Advisory Corp boosted its holdings in shares of ADMA Biologics by 1,081.6% in the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 2,293 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter worth approximately $46,000. Finally, Smartleaf Asset Management LLC grew its position in ADMA Biologics by 161.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,493 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Up 2.1%

ADMA stock opened at $19.80 on Wednesday. The business has a fifty day moving average of $16.15 and a 200-day moving average of $17.25. The company has a market cap of $4.71 billion, a P/E ratio of 23.02 and a beta of 0.43. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The company’s revenue was up 12.0% on a year-over-year basis. During the same period last year, the company earned $0.15 earnings per share. As a group, equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.